SCHEMBL19786871

SCHEMBL19786871

Oc1ccc(-c2cnc3c(NCCNCl)nc4ccccc4n23)cc1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 7/20 0.40
CHUK O15111 7/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ADORA1 P30542 2/20 0.39
ADORA2A P29274 1/20 0.39
BRD4 O60885 5/20 0.37
MIF P14174 1/20 0.37
ERN1 O75460 1/20 0.36
RPS6KA4 O75676 1/20 0.36
PRKD3 O94806 1/20 0.36
CDK1 P06493 1/20 0.36
KIT P10721 1/20 0.36
CDK11B P21127 1/20 0.36
CDK2 P24941 1/20 0.36
TYK2 P29597 1/20 0.36
CSNK1D P48730 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17895237 0.89 BRD4 (0.47) IKBKBCHUKMEN1KMT2ARXFP1
SCHEMBL17895085 0.89 IKBKB (0.48) IKBKBCHUKMEN1KMT2ARXFP1
SCHEMBL17895072 0.87 BRD4 (0.49) IKBKBCHUKBRD4ERN1RPS6KA4
SCHEMBL17895199 0.83 IKBKB (0.46) IKBKBCHUKADORA1ADORA2AMIF
SCHEMBL22099675 0.81 BRD4 (0.40) BRD4
SCHEMBL22099671 0.81 BRD4 (0.40) BRD4
SCHEMBL17895272 0.78 ALDH1A1 (0.37) IKBKBCHUKADORA1ADORA2ABRD4
SCHEMBL17894987 0.77 BRD4 (0.41) IKBKBCHUKBRD4ERN1RPS6KA4
SCHEMBL17895310 0.77 IKBKB (0.45) IKBKBCHUKBRD4ERN1RPS6KA4
SCHEMBL19786798 0.77 ADORA2A (0.37) IKBKBCHUKMEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer UNIVERSITE DE MONTPELLIER (FR) 2020-06-23 US disclosed
US-20180016278-A1 Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689384-B2 Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer NQO1, NQO2, ABL1 IKBKB 1832/4885CHUK 1133/4885MEN1 599/4885
US-20180016278-A1 Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer NQO1, NQO2, ABL1 IKBKB 1832/4885CHUK 1133/4885MEN1 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.